Journal of Neural Transmission

Article	Citations
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study	106
Facets of movement disorders– a tribute to Heinz Reichmann	99
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?	73
Proteinopathies: molecular mechanisms and diagnostic perspectives	64
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease	63
Movement disorders associated with diarrhoea	61
Contrasting features between Tourette syndrome and secondary tic disorders	60
Eye movement study in essential tremor patients and its clinical correlates	59
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study	58
Dopamine agonists in the treatment of Parkinson's disease: the show must go on	51
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes	51
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease	48
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary	47
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:	46
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers	44
Current perspectives on brain circuits involved in food addiction-like behaviors	42
Distinct gait dimensions are modulated by physical activity in Parkinson's disease patients	41
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery	40
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up	39
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study	38
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion	37
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons	34
Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity	32
Botulinum toxin for chronic migraine	32
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease	31

Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia	30
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey	29
Understanding cognitive features of cervical dystonia: application of the cerebellar cognitive affective syndrome scale (CCAS-S)	29
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016	28
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease	27
The pathobiology of depression in Huntington’s disease: an unresolved puzzle	27
Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!	27
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view	26
Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy	24
Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report	24
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease	24
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research	22
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients	22
Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review	22
Constipation and pain in Parkinson’s disease: a clinical analysis	22
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic	21
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease	21
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study	21
Insulin resistance: fueling oxidative stress and neurodegeneration	20
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy	19
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy	19
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures	18
Illness perceptions in pre-operative Parkinson’s disease patients	18
Axial postural abnormalities and pain in Parkinson’s disease	18
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice	18
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders	17
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing	17
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice	17
Language in autism: domains, profiles and co-occurring conditions	17
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand	17
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa	17
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study	16
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study	16
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events	16
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet	16
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia	15
Neuroscience and addiction research: current advances and perspectives	15
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression	15
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro	15
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration	14
Pharmacogenetics in advanced Parkinson’s disease	14
Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease	14
Update on sleep disorders in advanced Parkinson’s disease: a narrative review	14
Proteinopathies associated to repeat expansion disorders	14
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study	14
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention	14
Linking diet, gut microbiota, and metabolites to Parkinson’s disease risk: a shotgun metagenomic comparison of Japanese and Taiwanese cohorts	14
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone	14
Prenatal exposure to morphine enhances excitability in locus coeruleus neurons	14
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study	14

Sex differences in schizophrenia: a longitudinal methylome analysis	13
Increased hair cortisol in mothers of children with ADHD symptoms and psychosocial adversity background	13
Resting-state EEG changes associated with cognitive decline in Parkinson’s disease: a systematic review	13
Superoxide dismutase isozymes in cerebral organoids from autism spectrum disorder patients	13
Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study	13
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease	13
The natural course of idiopathic cervical dystonia	13
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment	12
Sexual dysfunction in men with young onset Parkinson's disease	12
Tips and tricks in tremor treatment	12
Exploring transferability in psychiatric interventions: a conceptual framework	12
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia	12
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease	12
From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview	12
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability	12
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease	12
Therapeutic use of medical Cannabis in neurological diseases: a clinical update	11
Unveiling the link between chronic pain and misuse of opioids and cannabis	11
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala	11
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide	11
Memantine: updates from the past decade and implications for future novel therapeutic applications	11
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA	11
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes	11
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease	11
Writing tremor in Parkinson’s disease: frequency and associated clinical features	11
Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels	11
Pesticides and parkinson’s disease: causal relationship at the population and individual level?	11
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS	11
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease	11
Parkinson’s disease, aerobic exercise and photobiomodulation: a randomised controlled trial	11
If you can't be with the one you love, love the one you're with (C, S, N & Y)	10
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations	10
The prevalence of gastrointestinal dysfunction and its impact on quality of life in Parkinson’s disease	10
Depression and anxiety in multiple sclerosis. Review of a fatal combination	10
Plasma prolactin and symptoms of schizophrenia	10
Oligodendrocytes matter: a review of animal studies on early adversity	10
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study	10
Mild cognitive impairment in amyotrophic lateral sclerosis: current view	10
Posttraumatic growth and wellbeing in three countries after COVID-19: analysis using a random intercept cross-lagged panel model	10
Depression in dementia with Lewy bodies: a critical update	10
EEG neurosubtyping of infants predicts language trajectories	10
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study	10
Neuromarkers in addiction: definitions, development strategies, and recent advances	10
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain	10
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A	10
The brain and heart-axis in neurodegeneration and cardiovascular disease	10
MEF2C gene variations are associated with ADHD in the Chinese Han population: a case–control study	9
Mild cognitive impairment in Huntington’s disease: challenges and outlooks	9
Psychotherapies in opioid use disorder: toward a step-care model	9
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease	9
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes	9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease	9
Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study	9
Mediating roles of attention-deficit/hyperactivity disorder symptom severity and self-control on the relationship between adverse childhood experiences and adult aggression	9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index	9
Treatment; Moussa B.H. Youdim	9
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study	9
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders	9
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states	9
Advanced is advanced is advanced is advanced	9
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	9
The pathobiological basis of depression in Parkinson disease: challenges and outlooks	8
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview	8
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t	8
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype	8
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?	8
Cognition and Activity of Daily Living Function in people with Parkinson’s disease	8
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice	8
The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder	8
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study	8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates	8
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease	8
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis	8
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model	8
The heterogeneity of Parkinson’s disease	8
Locus Coeruleus magnetic resonance imaging: a comparison between native-space and template-space approach	8
Mild cognitive impairment in multiple system atrophy: a brain network disorder	8
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease	8
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome	8
Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson’s disease in Germany and the needs of future development	7

Deep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review	7
Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network	7
Clinical utility of digital technologies in Parkinson’s disease	7
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review	7
Interrater reliability of motor severity scales for hemifacial spasm	7
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome	7
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?	7
Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study	7
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease	7
Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications	7
Botulinum toxin therapy: past, present and future developments	7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities	7
Lifestyle medicine in Parkinson’s disease	7
Driving innovation in addiction treatment: role of transcranial magnetic stimulation	7
Nicotinic regulation of microglia: potential contributions to addiction	7
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder	7
Association between alcohol consumption and mortality in Parkinson’s disease	7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease	7
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease	7
Vascular parkinsonism: an update	7
GBA-associated PD: chances and obstacles for targeted treatment strategies	7
Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians	7
Plasma concentrations of anti-inflammatory cytokine TGF-β are associated with hippocampal structure related to explicit memory performance in older adults	7
Concomitant pathologies and their impact on Huntington’s disease. A brief review of current evidence	7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention	7
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone	7
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?	7
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease	7
New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic	6
Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis	6
Elucidating the crystal structure of botulinum neurotoxin type A: a personal remembrance	6
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?	6
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016	6
Correction: Insulin resistance: fueling oxidative stress and neurodegeneration	6
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration	6
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review	6
Identification of DAGLB variants in Japanese early-onset Parkinson’s disease	6
Correction: Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction	6
Correction to: Common network effect‑patterns after monoamine reuptake inhibition in dissociated hippocampus cultures	6
Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer’s disease-like pathology	6
Clinical correlates of pareidolias and color discrimination deficits in idiopathic REM sleep behavior disorder and Parkinson’s disease	6
Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches	6
Reduced interleukin-6 stress reactivity in male physicians with occupational burnout	6
MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia	6
Predisposing factors to pattern change in cervical dystonia	6
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry	6
Probing the properties of PTEN specific botulinum toxin type E mutants	6
The relationship between sphingomyelin and ceramide levels and soft neurological signs in ADHD	5
Is the vertex a good control stimulation site? Theta burst stimulation in healthy controls	5
Brain instability in dynamic functional connectivity in schizophrenia	5
Disease modification in Parkinsonism: obstacles and ways forward	5
Steroid hormone pathways, vitamin D and autism: a systematic review	5
The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder	5
Movement disorders: a brief overview from an evolutionary perspective	5
Multilevel and multimodal biobehavioral methods in the study of stress, trauma, and resilience: a systems approach	5
Prof. DDr. Gregor K. Wenning (1964–2024)	5
Excessive psychological stress preceding the onset of idiopathic cervical dystonia	5
Viruses, parkinsonism and Parkinson’s disease: the past, present and future	5
Essential tremor plus rest tremor: current concepts and controversies	5
Sex- and age-specific prevalence and risk factors of depressive symptoms in Parkinson’s disease	5
Effects of levodopa–entacapone–carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson’s disease—interim analysis of the ELEGANCE study	5
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson’s disease	5
Editorial for Emeritus Professor Yoshikuni Mizuno	5
Behavioral disorders in Parkinson disease: current view	5
Mitochondrial dysfunction in Parkinson’s disease	5
Neural bases characterizing chronic and severe upper-limb motor deficits after brain lesion	5
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein	5
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress	5
Clinical and kinematic characterization of parkinsonian soft signs in essential tremor	5
A cross-language speech model for detection of Parkinson’s disease	5
The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	5
The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice	5
Cumulative hardship: the role of perceived injustice in linking war-related trauma and discrimination with mental health	5
Neurobiological mechanisms of dialectical behavior therapy and Morita therapy, two psychotherapies inspired by Zen	5
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study	5
The effectiveness of non-invasive brain stimulation in treatment of major depressive disorder (MDD): a systematic review and transfer analysis	4
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies	4
Modulatory effect of olanzapine on neuronal nitric oxide synthase (nNOS) expression in the rat striatum	4
Correction to: Proteinopathies: molecular mechanisms and diagnostic perspectives	4
Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychothe	4
More than fear? Brain activation patterns of dental phobic patients before and after an exposure-based treatment	4
Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats	4
Action impulsivity and attention deficits in patients at an early stage of Huntington disease	4
Deep brain stimulation for psychostimulant use disorders	4
Altered domain-specific striatal functional connectivity in patients with Parkinson’s disease and urinary symptoms	4
The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models	4
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pha	4
Peter Riederer, a translational neurobiochemist	4
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study	4
Declining incidence of Parkinson’s disease in Israel (2002–2021)	4
Neuroplasticity in Parkinson’s disease	4
Challenges in the treatment of Tourette syndrome in the Philippines	4
The ‘α-synucleinopathy syndicate’: multiple system atrophy and Parkinson’s disease	4
Genetic testing for Parkinson’s disease in clinical practice	4
Elevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation	4